# A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

> **NCT00929370** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 34 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Glycine Transporter-1 inhibitor

## Key facts

- **NCT ID:** NCT00929370
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2008-10
- **Final completion:** 2009-03
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Study has now been terminated due to changes in project strategy. Current available data will be analysed and reported in a synoptic study report.
- **Last updated:** 2009-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00929370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00929370, "A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00929370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*